A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.

Rahul R AggarwalMichael T SchweizerDavid M NanusAllan J PantuckElisabeth I Heath Eric CampeauSarah AttwellKaren NorekMargo SnyderLisa BaumanSanjay LakhotiaFelix Y FengEric J SmallWassim AbidaJoshi J Alumkal

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

ZEN-3694 plus enzalutamide demonstrated acceptable tolerability and potential efficacy in patients with ASI-resistant mCRPC. Further prospective study is warranted including in mCRPC harboring low AR transcriptional activity.

Keyphrases

prostate cancer
gene expression
open label
randomized controlled trial
clinical trial
heat shock
climate change